Active substance Levetiracetam
US Brand Keppra
IN Brand Levipil / Levera
Manufacturing by Sun Pharma / Intas
Strength 750mg
Form release Blister 10 tab
Shipping time 7 – 18 days (Depending from the Country)
Availability & Order through request form
Make request

 

DescriptionDosageSide EffectsPhotos

Levetiracetam has been approved in the United States as add-on treatment for partial (focal), myoclonic, and tonic-clonic seizures. Levetiracetam has been approved in the European Union as a monotherapy treatment for epilepsy in the case of partial seizures, or as an adjunctive therapy for partial, myoclonic, and tonic-clonic seizures.  Levipil has been shown to reduce partial (focal) seizures by 50% or more as an add-on medication. It is also used in veterinary medicine for similar purposes.

Levetiracetam is sometimes used off-label to treat status epilepticus  or to prevent seizures associated with subarachnoid hemorrhages.

Levetiracetam has potential benefits for other psychiatric and neurologic conditions such as Tourette syndrome,  anxiety disorder, and Alzheimer’s disease. However, its most serious adverse effects are behavioral, and its benefit-risk ratio in these conditions is not well understood.

Levetiracetam has not been found to be useful for treatment of neuropathic pain, nor for treatment of essential tremors. Levetiracetam has not been found to be useful for treating autism, but is an effective treatment for partial, myoclonic, or tonic-clonic seizures associated with autism spectrum disorder.

Usual Adult Dose for Epilepsy

PARTIAL ONSET SEIZURES:
-IV: 1000 mg daily given as 500 mg 2 times a day: increase in increments of 1000 mg/day every 2 weeks to the maximum daily dose of 3000 mg. There is no evidence that doses greater than 3000 mg/day confer additional benefit.
-ORAL IMMEDIATE-RELEASE: 1000 mg daily given as 500 mg 2 times a day; increase in increments of 1000 mg/day every 2 weeks to the maximum daily dose of 3000 mg. There is no evidence that doses greater than 3000 mg/day confer additional benefit.
-ORAL EXTENDED-RELEASE: 1000 mg once a day; increase in increments of 1000 mg every 2 weeks to the maximum daily dose of 3000 mg

MYOCLONIC SEIZURES IN PATIENTS WITH JUVENILE MYOCLONIC EPILEPSY:
-IV: 1000 mg daily given as 500 mg 2 times a day; increase in increments of 1000 mg/day every 2 weeks to the maximum daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.
-ORAL IMMEDIATE-RELEASE: 1000 mg/day, given as twice daily dosing (500 mg 2 times a day); increase in increments of 1000 mg/day every 2 weeks to the maximum daily dose of 3000 mg/day. The effectiveness of doses lower than 3000 mg/day has not been studied.

PRIMARY GENERALIZED TONIC-CLONIC SEIZURES:
IV: 1000 mg daily given as 500 mg 2 times a day; increase in increments of 1000 mg/day every 2 weeks to the maximum daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.
-ORAL IMMEDIATE-RELEASE: 1000 mg/day, given as twice daily dosing (500 mg 2 times a day); increase in increments of 1000 mg/day every 2 weeks to the maximum daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.

Uses:
-Adjunct therapy in the treatment of partial onset seizures in patients with epilepsy
-Adjunctive therapy in the treatment of juvenile myoclonic epilepsy
-Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with idiopathic generalized epilepsy

Usual Adult Dose for Seizures

PARTIAL ONSET SEIZURES:
-IV: 1000 mg daily given as 500 mg 2 times a day: increase in increments of 1000 mg/day every 2 weeks to the maximum daily dose of 3000 mg. There is no evidence that doses greater than 3000 mg/day confer additional benefit.
-ORAL IMMEDIATE-RELEASE: 1000 mg daily given as 500 mg 2 times a day; increase in increments of 1000 mg/day every 2 weeks to the maximum daily dose of 3000 mg. There is no evidence that doses greater than 3000 mg/day confer additional benefit.
-ORAL EXTENDED-RELEASE: 1000 mg once a day; increase in increments of 1000 mg every 2 weeks to the maximum daily dose of 3000 mg

MYOCLONIC SEIZURES IN PATIENTS WITH JUVENILE MYOCLONIC EPILEPSY:
-IV: 1000 mg daily given as 500 mg 2 times a day; increase in increments of 1000 mg/day every 2 weeks to the maximum daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.
-ORAL IMMEDIATE-RELEASE: 1000 mg/day, given as twice daily dosing (500 mg 2 times a day); increase in increments of 1000 mg/day every 2 weeks to the maximum daily dose of 3000 mg/day. The effectiveness of doses lower than 3000 mg/day has not been studied.

PRIMARY GENERALIZED TONIC-CLONIC SEIZURES:
IV: 1000 mg daily given as 500 mg 2 times a day; increase in increments of 1000 mg/day every 2 weeks to the maximum daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.
-ORAL IMMEDIATE-RELEASE: 1000 mg/day, given as twice daily dosing (500 mg 2 times a day); increase in increments of 1000 mg/day every 2 weeks to the maximum daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.

Uses:
-Adjunct therapy in the treatment of partial onset seizures in patients with epilepsy
-Adjunctive therapy in the treatment of juvenile myoclonic epilepsy
-Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with idiopathic generalized epilepsy

  • hallucinations, unusual thoughts or behavior;
  • bruising, severe tingling, numbness, pain, muscle weakness;
  • feeling very weak or tired;
  • fever, chills, body aches, flu symptoms, sores in your mouth and throat;
  • problems with walking or movement;